Division of Rheumatology, Department of Physical and Rehabilitation Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey.
Int J Rheum Dis. 2022 Jun;25(6):692-698. doi: 10.1111/1756-185X.14326. Epub 2022 May 6.
The primary goal of this study was to determine the prevalence of peripheral spondyloarthritis (pSpA) in patients with ultrasonography (USG)-confirmed enthesitis. The secondary aim of the study was to reveal the demographic, clinical, and ultrasonographic differences of patients diagnosed with pSpA.
Fifty-nine patients with USG-confirmed enthesitis were evaluated by a rheumatologist to evaluate if they met the Assessment of SpondyloArthritis International Society (ASAS) criteria for pSpA. Elementary lesions assessed by USG were based on the definition of the Outcome Measures in Rheumatology in Clinical Trials group which included hypoechogenicity, thickening, Doppler signal within 2 mm of bone, enthesophytes, bone erosions, and calcifications. For all patients, clinical and demographic data included: age, gender, smoking habits, body mass index, comorbid diseases, symptom duration, enthesitis region, the presence of bilateral enthesitis, entheseal pain visual analog scale (0-10), standardized enthesitis count following Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and SPondyloArthritis Research Consortium Canada (SPARCC) enthesitis index.
Eight (13.6%, 95% CI 6.0% to 25.0%) of 59 patients were diagnosed with pSpA according to the ASAS classification criteria. Participants diagnosed with pSpA had a longer duration of symptoms (54 vs 12 months), were more likely to present bilateral enthesitis (87.5% vs 49%) with higher SPARCC (11 vs 3) and MASES (6.5 vs 2) scores and higher C-reactive protein (7 vs 3.2 mg/L) concentrations. Entheseal Doppler signal and hypoechogenicity were also more frequently observed (50% vs 0% and 100% vs 49% respectively).
Peripheral SpA is not uncommon among patients presenting with enthesitis and more likely in cases with prolonged, extensive, and bilateral enthesitis with entheseal hypoechogenicity and Doppler signal. Musculoskeletal ultrasonography can facilitate the diagnosis of pSpA in patients presenting with enthesitis.
本研究的主要目的是确定超声(USG)证实的附着点炎患者外周脊柱关节炎(pSpA)的患病率。该研究的次要目的是揭示诊断为 pSpA 的患者的人口统计学、临床和超声差异。
59 例 USG 证实的附着点炎患者由风湿病学家进行评估,以评估他们是否符合评估脊柱关节炎国际协会(ASAS)的 pSpA 标准。USG 评估的基本病变基于临床疗效评估研究中的风湿病学终点测量指标(Outcome Measures in Rheumatology in Clinical Trials,OMERACT)小组的定义,包括低回声、增厚、距骨 2mm 内的多普勒信号、附着点骨赘、骨侵蚀和钙化。所有患者的临床和人口统计学数据包括:年龄、性别、吸烟习惯、体重指数、合并症、症状持续时间、附着点炎部位、双侧附着点炎的存在、附着点疼痛视觉模拟评分(0-10)、根据马斯特里赫特强直性脊柱炎附着点炎评分(Maastricht Ankylosing Spondylitis Enthesitis Score,MASES)和加拿大脊柱关节炎研究协会(SPondyloArthritis Research Consortium Canada,SPARCC)附着点炎指数进行标准化的附着点炎计数。
根据 ASAS 分类标准,59 例患者中 8 例(13.6%,95%置信区间 6.0%至 25.0%)被诊断为 pSpA。诊断为 pSpA 的患者症状持续时间更长(54 个月 vs 12 个月),更可能出现双侧附着点炎(87.5% vs 49%),SPARCC(11 分 vs 3 分)和 MASES(6.5 分 vs 2 分)评分更高,C 反应蛋白(CRP)浓度更高(7 毫克/升 vs 3.2 毫克/升)。附着点处的多普勒信号和低回声也更常见(分别为 50% vs 0%和 100% vs 49%)。
在出现附着点炎的患者中,外周 SpA 并不少见,在持续时间长、范围广、双侧附着点炎伴附着点低回声和多普勒信号的患者中更常见。肌肉骨骼超声检查有助于诊断出现附着点炎的患者的 pSpA。